Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa

Area of Science:

• Microbiology
• Medicinal Chemistry
• Pharmacology

Background:

• Gram-negative bacterial infections pose a significant public health threat, necessitating novel therapeutic strategies.
• LpxC, an enzyme in lipid A biosynthesis, is a validated target for antibacterial drug development.
• Existing treatments face challenges due to emerging resistance mechanisms.

Purpose of the Study:

• To discover and characterize novel inhibitors of LpxC with activity against Gram-negative pathogens, particularly *Pseudomonas aeruginosa*.
• To evaluate the *in vitro* antibacterial activity and pharmacodynamics of ACHN-975, a first-in-class LpxC inhibitor.
• To identify potential lead molecules for further drug development.

Main Methods:

• Extensive research campaign to identify LpxC inhibitors.
• In vitro antibacterial assays to determine efficacy.
• Pharmacodynamic studies to assess drug behavior in biological systems.

Main Results:

• ACHN-975 demonstrated *in vitro* antibacterial activity and was the first LpxC inhibitor to enter phase 1 clinical trials.
• Three additional LpxC inhibitors were identified as potential lead molecules.
• Despite promising initial findings, further development was discontinued due to an insufficient therapeutic window.

Conclusions:

• LpxC is a viable target for novel antibacterial agents against Gram-negative bacteria.
• ACHN-975 represents a significant advancement as the first LpxC inhibitor evaluated clinically.
• Challenges in achieving an adequate therapeutic window require further investigation for LpxC inhibitor development.